S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:ARAY

Accuray - ARAY Stock Forecast, Price & News

$2.05
-0.05 (-2.38%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.95
$2.07
50-Day Range
$1.88
$2.40
52-Week Range
$1.70
$5.41
Volume
508,960 shs
Average Volume
301,248 shs
Market Capitalization
$192.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Accuray MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
257.7% Upside
$7.33 Price Target
Short Interest
Bearish
5.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.28mentions of Accuray in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$231,493 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.02) to $0.12 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

347th out of 1,034 stocks

Surgical & Medical Instruments Industry

40th out of 104 stocks

ARAY stock logo

About Accuray (NASDAQ:ARAY) Stock

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Stock News Headlines

Accuray First Quarter 2023 Earnings: Misses Expectations
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
Accuray (NASDAQ: ARAY)
3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio
See More Headlines
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Company Calendar

Last Earnings
11/02/2021
Today
12/04/2022
Next Earnings (Estimated)
1/25/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
1,044
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+257.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-5,350,000.00
Pretax Margin
-1.55%

Debt

Sales & Book Value

Annual Sales
$429.91 million
Cash Flow
$0.01 per share
Book Value
$0.50 per share

Miscellaneous

Free Float
91,059,000
Market Cap
$192.25 million
Optionable
Optionable
Beta
1.62

Social Links


Key Executives

  • Ms. Suzanne  Winter M.B.A.Ms. Suzanne Winter M.B.A. (Age 59)
    Pres, CEO & Director
    Comp: $821.65k
  • Mr. Patrick R. SpineMr. Patrick R. Spine (Age 51)
    Sr. VP & Chief Admin. Officer
    Comp: $632.7k
  • Mr. Jesse  ChewMr. Jesse Chew (Age 41)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $621.12k
  • Mr. Joshua H. LevineMr. Joshua H. Levine (Age 64)
    Consultant
    Comp: $1.61M
  • Mr. Ali Pervaiz
    Sr. VP & CFO
  • Mr. Michael  HogeMr. Michael Hoge
    Sr. VP of Global Operations
  • Mr. Franco N. Palomba (Age 60)
    VP, Chief Accounting Officer & Controller
  • Dr. Jean-Philippe Pignol
    Sr. VP, Chief Medical & Technology Officer
  • Ken Mobeck
    VP of Fin. & Investor Relations
  • Beth Kaplan
    PR Director













ARAY Stock - Frequently Asked Questions

Should I buy or sell Accuray stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings
or view top-rated stocks.

What is Accuray's stock price forecast for 2023?

3 brokerages have issued 1 year target prices for Accuray's shares. Their ARAY share price forecasts range from $7.00 to $7.50. On average, they anticipate the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 257.7% from the stock's current price.
View analysts price targets for ARAY
or view top-rated stocks among Wall Street analysts.

How have ARAY shares performed in 2022?

Accuray's stock was trading at $4.77 at the beginning of the year. Since then, ARAY shares have decreased by 57.0% and is now trading at $2.05.
View the best growth stocks for 2022 here
.

When is Accuray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our ARAY earnings forecast
.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) posted its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. The medical equipment provider earned $107.44 million during the quarter. Accuray had a negative net margin of 2.33% and a negative trailing twelve-month return on equity of 19.27%.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2023 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $447.00 million-$455.00 million, compared to the consensus revenue estimate of $450.03 million.

What is Joshua Levine's approval rating as Accuray's CEO?

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of institutional and retail investors. Top institutional investors include Neuberger Berman Group LLC (5.59%), Vanguard Group Inc. (4.29%), Renaissance Technologies LLC (3.98%), BlackRock Inc. (3.59%), Royce & Associates LP (2.91%) and Heartland Advisors Inc. (2.66%). Insiders that own company stock include Ali Pervaiz, Andrew J Kirkpatrick, Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends
.

How do I buy shares of Accuray?

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.05.

How much money does Accuray make?

Accuray (NASDAQ:ARAY) has a market capitalization of $192.25 million and generates $429.91 million in revenue each year. The medical equipment provider earns $-5,350,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Accuray have?

The company employs 1,044 workers across the globe.

Does Accuray have any subsidiaries?
The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More
How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The official website for the company is www.accuray.com. The medical equipment provider can be reached via phone at (408) 716-4600, via email at mpolyviou@evcgroup.com, or via fax at 408-716-4601.

This page (NASDAQ:ARAY) was last updated on 12/4/2022 by MarketBeat.com Staff